288 related articles for article (PubMed ID: 32648697)
21. Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry.
Klein A; Becker I; Minden K; Foeldvari I; Haas JP; Horneff G
Scand J Rheumatol; 2019 Mar; 48(2):95-104. PubMed ID: 30411654
[TBL] [Abstract][Full Text] [Related]
22. Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan.
Imagawa T; Takei S; Umebayashi H; Yamaguchi K; Itoh Y; Kawai T; Iwata N; Murata T; Okafuji I; Miyoshi M; Onoe Y; Kawano Y; Kinjo N; Mori M; Mozaffarian N; Kupper H; Santra S; Patel G; Kawai S; Yokota S
Clin Rheumatol; 2012 Dec; 31(12):1713-21. PubMed ID: 23053683
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: A single-centre cohort study using routinely collected health data.
Alexeeva E; Krekhova E; Dvoryakovskaya T; Isaeva K; Chomakhidze A; Chistyakova E; Lomakina O; Denisova R; Mamutova A; Fetisova A; Gautier M; Vankova D; Kriulin I; Saygitov R
Front Pediatr; 2023; 11():1114207. PubMed ID: 36911042
[TBL] [Abstract][Full Text] [Related]
24. Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children's Health, Russia.
Alexeeva EI; Namazova-Baranova LS; Bzarova TM; Valieva SI; Denisova RV; Sleptsova TV; Isaeva KB; Chomahidze AM; Taibulatov NI; Fetisova AN; Karaseva AV; Baranov AA
Pediatr Rheumatol Online J; 2017 Jun; 15(1):51. PubMed ID: 28615036
[TBL] [Abstract][Full Text] [Related]
25. Development and validation of a composite disease activity score for juvenile idiopathic arthritis.
Consolaro A; Ruperto N; Bazso A; Pistorio A; Magni-Manzoni S; Filocamo G; Malattia C; Viola S; Martini A; Ravelli A;
Arthritis Rheum; 2009 May; 61(5):658-66. PubMed ID: 19405003
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study.
Vastert SJ; de Jager W; Noordman BJ; Holzinger D; Kuis W; Prakken BJ; Wulffraat NM
Arthritis Rheumatol; 2014 Apr; 66(4):1034-43. PubMed ID: 24757154
[TBL] [Abstract][Full Text] [Related]
27. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.
De Benedetti F; Brunner HI; Ruperto N; Kenwright A; Wright S; Calvo I; Cuttica R; Ravelli A; Schneider R; Woo P; Wouters C; Xavier R; Zemel L; Baildam E; Burgos-Vargas R; Dolezalova P; Garay SM; Merino R; Joos R; Grom A; Wulffraat N; Zuber Z; Zulian F; Lovell D; Martini A; ;
N Engl J Med; 2012 Dec; 367(25):2385-95. PubMed ID: 23252525
[TBL] [Abstract][Full Text] [Related]
28. Outcome of children with oligoarticular juvenile idiopathic arthritis compared to polyarthritis on methotrexate- data of the German BIKER registry.
Raab A; Kallinich T; Huscher D; Foeldvari I; Weller-Heinemann F; Dressler F; Kuemmerle-Deschner JB; Klein A; Horneff G
Pediatr Rheumatol Online J; 2021 Mar; 19(1):41. PubMed ID: 33752685
[TBL] [Abstract][Full Text] [Related]
29. Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years.
Kingsbury DJ; Bader-Meunier B; Patel G; Arora V; Kalabic J; Kupper H
Clin Rheumatol; 2014; 33(10):1433-41. PubMed ID: 24487484
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.
Horneff G; Foeldvari I; Minden K; Trauzeddel R; Kümmerle-Deschner JB; Tenbrock K; Ganser G; Huppertz HI
Arthritis Rheumatol; 2015 May; 67(8):2240-9. PubMed ID: 25891010
[TBL] [Abstract][Full Text] [Related]
31. Distinct Gene Expression Signatures Characterize Strong Clinical Responders Versus Nonresponders to Canakinumab in Children With Systemic Juvenile Idiopathic Arthritis.
Verweyen EL; Pickering A; Grom AA; Schulert GS
Arthritis Rheumatol; 2021 Jul; 73(7):1334-1340. PubMed ID: 33452871
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups.
Feist E; Quartier P; Fautrel B; Schneider R; Sfriso P; Efthimiou P; Cantarini L; Lheritier K; Leon K; Karyekar CS; Speziale A
Clin Exp Rheumatol; 2018; 36(4):668-675. PubMed ID: 29533755
[TBL] [Abstract][Full Text] [Related]
33. S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis.
Brunner HI; Schulert GS; Sproles A; Thornton S; Cornejo GV; Antón J; Cuttica R; Henrickson M; Foeldvari I; Kingsbury DJ; Askelson M; Liu J; Mukherjee S; Wong RL; Lovell DJ; Martini A; Ruperto N; Grom AA;
Arthritis Res Ther; 2024 Jun; 26(1):125. PubMed ID: 38918871
[TBL] [Abstract][Full Text] [Related]
34. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
Yokota S; Imagawa T; Mori M; Miyamae T; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
J Rheumatol; 2014 Apr; 41(4):759-67. PubMed ID: 24634205
[TBL] [Abstract][Full Text] [Related]
35. Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab.
Grom AA; Ilowite NT; Pascual V; Brunner HI; Martini A; Lovell D; Ruperto N; ; Leon K; Lheritier K; Abrams K
Arthritis Rheumatol; 2016 Jan; 68(1):218-28. PubMed ID: 26314396
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials.
Tarp S; Amarilyo G; Foeldvari I; Christensen R; Woo JM; Cohen N; Pope TD; Furst DE
Rheumatology (Oxford); 2016 Apr; 55(4):669-79. PubMed ID: 26628580
[TBL] [Abstract][Full Text] [Related]
37. Performance of rheumatoid arthritis disease activity measures and juvenile arthritis disease activity scores in polyarticular-course juvenile idiopathic arthritis: Analysis of their ability to classify the American College of Rheumatology pediatric measures of response and the preliminary criteria for flare and inactive disease.
Ringold S; Bittner R; Neogi T; Wallace CA; Singer NG
Arthritis Care Res (Hoboken); 2010 Aug; 62(8):1095-102. PubMed ID: 20506561
[TBL] [Abstract][Full Text] [Related]
38. Outcome and Trends in Treatment of Systemic Juvenile Idiopathic Arthritis in the German National Pediatric Rheumatologic Database, 2000-2013.
Klotsche J; Raab A; Niewerth M; Sengler C; Ganser G; Kallinich T; Niehues T; Hufnagel M; Thon A; Hospach T; Horneff G; Minden K
Arthritis Rheumatol; 2016 Dec; 68(12):3023-3034. PubMed ID: 27332999
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.
Yokota S; Imagawa T; Mori M; Miyamae T; Aihara Y; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
Lancet; 2008 Mar; 371(9617):998-1006. PubMed ID: 18358927
[TBL] [Abstract][Full Text] [Related]
40. Long-term, interventional, open-label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Poland and Russia who completed the global, international CHERISH trial.
Opoka-Winiarska V; Żuber Z; Alexeeva E; Chasnyk V; Nikishina I; Dębowska G; Smolewska E
Clin Rheumatol; 2018 Jul; 37(7):1807-1816. PubMed ID: 29654485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]